Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD). Chemically speaking, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.It was approved for medical use in the United States in April 2006, as Myozyme and in May 2010, as Lumizyme. Medical uses
Alglucosidase alfa is indicated for people with Pompe disease (GAA deficiency).In 2014 the U.S. Food and Drug Administration announced the approval of alglucosidase alfa for treatment of people with infantile-onset Pompe disease, including people who are less than eight years of age. In addition, the Risk Evaluation and Mitigation Strategy (REMS) is being eliminated. Side effects
Common observed adverse reactions to alglucosidase alfa treatment are pneumonia, respiratory complications, infections and fever. More serious reactions reported include heart and lung failure and allergic shock. Myozyme boxes carry warnings regarding the possibility of life-threatening allergic response. Cost
Some health plans have refused to subsidize Myozyme for adults because it lacks approval for treatment in adults, as well as its high cost (US$300,000 per year for life).In 2015, Lumizyme was ranked the costliest drug per patient, with an average charge of $630,159. References
External links
"Alglucosidase Alfa". Drug Information Portal. U.S. National Library of Medicine.
Parapsoriasis refers to one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying cause. Neoplasms can develop from parapsoriasis. For example, it can develop into cutaneous T-cell lymphoma. The word "parapsoriasis" was formed in 1902. Classification
The parapsoriasis groups, described and debated for nearly a century, has spawned a confusing nomenclature. There are some authors who prefer to limit the term "parapsoriasis" to large- and small-plaque variants only. However, the following classification scheme is now generally accepted:: 450 
Large-plaque parapsoriasis
Small-plaque parapsoriasis
Pityriasis lichenoides
Pityriasis lichenoides chronica
Pityriasis lichenoides et varioliformis acuta
Lymphomatoid papulosis

See also
Poikiloderma vasculare atrophicans
List of cutaneous conditions

References


== External links ==